287 related articles for article (PubMed ID: 33475078)
1. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract][Full Text] [Related]
2. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
3. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
4. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract][Full Text] [Related]
5. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
6. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A; Bossaer JB
J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
[TBL] [Abstract][Full Text] [Related]
7. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
8. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
[TBL] [Abstract][Full Text] [Related]
10. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Loriot Y; O'Hagan A; Siefker-Radtke AO
Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
[TBL] [Abstract][Full Text] [Related]
11. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
13. Erdafitinib exerts the anticancer effect on urothelial carcinoma
Jin YY; Tong SQ; Tong M
Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
15. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Siefker-Radtke AO; Loriot Y
Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
[No Abstract] [Full Text] [Related]
16. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
18. Erdafitinib to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
[TBL] [Abstract][Full Text] [Related]
19. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
Franza A; Pirovano M; Giannatempo P; Cosmai L
Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
[TBL] [Abstract][Full Text] [Related]
20. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Benjamin DJ; Hsu R
Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
